23andMe IPF Research Study

Sponsor

23andMe, Inc. (Industry)

Overall Status

Recruiting

CT.gov ID

NCT05028894

Collaborator

(none)

1,000

Enrollment

Location

25.9

Anticipated Duration (Months)

38.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The long term goal of this study is to increase genetic understanding of IPF to enable the development of an effective drug for IPF that can improve the lives of those living with the condition.

Condition or Disease	Intervention/Treatment	Phase
Idiopathic Pulmonary Fibrosis	Other: No intervention

Detailed Description

This study will recruit 1,000 people who have been diagnosed with IPF or Hermansky-Pudlak syndrome (HPS). Eligible participants who consent to participate in 23andMe Research and the IPF Research Study will receive a 23andMe Health + Ancestry kit at no cost. Participants will provide a saliva sample and take a baseline survey online answering questions about their disease diagnosis, testing, treatment, and symptoms. Participants will also be asked to take the same survey 3, 6, and 9 months after completing the baseline survey. The data collected from this study will be incorporated into the 23andMe Database and used to better understand the underlying genetic and environmental factors that contribute to IPF.

Study Design

Study Type:

Observational [Patient Registry]

Anticipated Enrollment :

1000 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

23andMe Idiopathic Pulmonary Fibrosis Research Study

Actual Study Start Date :

Jun 5, 2020

Anticipated Primary Completion Date :

Nov 1, 2021

Anticipated Study Completion Date :

Aug 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
IPF Participants diagnosed with idiopathic pulmonary fibrosis	Other: No intervention No intervention

Arm

Intervention/Treatment

IPF

Participants diagnosed with idiopathic pulmonary fibrosis

Other: No intervention

No intervention

Outcome Measures

Primary Outcome Measures

IPF Symptom Progression Baseline [Baseline]
Survey asking about disease diagnosis, testing, treatments, and symptom progression
IPF Symptom Progression 3 month follow-up [3 months post baseline]
IPF Symptom Progression 3 month follow-up
IPF Symptom Progression 6 month follow-up [6 months post baseline]
Survey asking about disease diagnosis, testing, treatments, and symptom progression
IPF Symptom Progression 9 month follow-up [9 months post baseline]
Survey asking about disease diagnosis, testing, treatments, and symptom progression